Professional Education
- B.A., Oxford University Zoology
- Ph.D., Harvard University Biochemistry & Molecular Biology
- Postdoc., University of Geneva Biologie Moleculaire
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Web Site Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Pain Therapeutics, Inc.
Research Interests
Our current research is focused on development of novel vectors and strategies for gene therapy. Our primary approach is development of vectors that will integrate at specific sites in the genome. We use the phiC31 phage integrase to mediate genomic integration. We are improving the basic technology, as well as applying it to a diverse set of tissues and diseases.
We are currently delivering integrating plasmid DNA vectors using naked DNA and in vivo and ex vivo electroporation. We are working with animal models for diseases involving blood, eye, muscle, liver, and other tissues.
Publications
- Gene Ther. 2009;
- Mol Ther. 2009; (1): 112-20
- Curr Opin Mol Ther. 2008; (5): 464-70
- J Neurosci Methods. 2008; (2): 299-305
- Methods Mol Biol. 2008; 165-73
- Nat Protoc. 2007; (10): 2325-31
- Invest Ophthalmol Vis Sci. 2006; (9): 4083-90
- Hum Gene Ther. 2006; (8): 871-6
- Proc Natl Acad Sci U S A. 2006; (2): 419-24
- Curr Gene Ther. 2006; (6): 633-45
- J Gene Med. 2006; (8): 1008-17
- Mol Genet Genomics. 2006; (2): 135-46
- J Mol Biol. 2006; (1): 28-48
- Invest Ophthalmol Vis Sci. 2005; (6): 2140-6
- Adv Genet. 2005; 179-87
- Genetics. 2004; (4): 1775-82
- J Mol Biol. 2004; (3): 667-78
- Biotechnol Prog. 2003 Jan-Feb; (1): 144-51
- Reprod Biol Endocrinol. 2003; 79
- Curr Opin Mol Ther. 2003; (4): 376-82
- Hum Gene Ther. 2003; (9): 923-8
- Nat Biotechnol. 2002; (11): 1124-8
- J Bacteriol. 2002; (13): 3657-63
- Curr Opin Mol Ther. 2002; (4): 299-305
- Nat Med. 2002; (10): 1166-70
- Nucleic Acids Res. 2001; (24): 5044-51
- Gene. 2001; (1-2): 167-76
- Mol Ther. 2001; (2): 122-9
- Mol Cell Biol. 2001; (12): 3926-34
- Proc Natl Acad Sci U S A. 2000; (11): 5995-6000
- Gene. 2000; (1-2): 47-54
- Nucleic Acids Res. 2000; (17): E80
- Plasmid. 1999; (3): 198-206
- Somat Cell Mol Genet. 1999; (2): 91-100
- Current Opinion Biotechnology. 1998;
- Curr Opin Biotechnol. 1998; (5): 476-9
- Proc Natl Acad Sci U S A. 1998; (8): 4084-5
- Arch Virol. 1998; (3): 563-70
- Adv Drug Deliv Rev. 1998; (1-3): 13-21
- Trends Genet. 1996; (11): 463-6
- Gene Ther. 1996; (6): 503-12
- Mol Cell Biol. 1995; (9): 5165-72
- Chromosoma. 1995; (9): 597-605
- Mol Cell Biol. 1994; (4): 2516-24
- Mol Biol Cell. 1994; (8): 839-49
- Mol Cell Biol. 1994; (3): 1796-805
- Chromosoma. 1993; (2): 129-36
- Mol Cell Biol. 1993; (5): 2688-96
- Gene. 1993; (1-2): 137-43
- Nucleic Acids Res. 1992; (22): 5971-8
- Mol Cell Biol. 1991; (3): 1464-72
- Mol Cell Biol. 1991; (4): 2263-72
- Nucleic Acids Res. 1991; (18): 5053-8
- Mutat Res. 1989 Mar-May; (2-3): 125-32
- Mol Cell Biol. 1989; (3): 1026-33
- J Virol. 1988; (10): 3738-46
- Mutagenesis. 1988; (1): 1-9